Treatment for Cisplatin-Ineligible Patients with High PD-L1 Expression

Video

Petros Grivas, MD, PhD, shares a clinical scenario of a cisplatin-ineligible patient with high PD-L1 expression and lymph node metastases, and experts weigh in on recommended treatment options.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Recent Videos
      5 experts in this video
      The Future of DLBCL: Innovations in Therapy and Patient Care
      Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
      Reviewing QOL Strategies/Considerations Following Bladder Cancer Surgery
      4 experts in this video
      Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
      4 experts in this video
      Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
      Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
      Outlining Risk Factor Identification and Mitigation in Bladder Cancer
      5 experts in this video
      CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease
      4 experts in this video
      PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
      5 experts in this video
      Transplant-Eligible, CAR T Considered: How Do We Decide?
      4 experts in this video
      The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
      5 experts in this video
      Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL
      Related Content
      FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

      FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

      Ariana Pelosci
      March 28th 2025
      Article

      Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.

      NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

      NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
      March 4th 2025
      Podcast

      The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

      UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

      UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

      Tim Cortese
      March 11th 2025
      Article

      In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

      Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

      Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

      Matthew Fowler;Jun Gong, MD
      March 15th 2022
      Podcast

      Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

      Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

      EV-302 Supports Enfortumab Vedotin Plus Pembrolizumab as Bladder Cancer SOC

      Russ Conroy
      February 25th 2025
      Article

      Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

      Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

      Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

      Ashling Wahner
      February 15th 2025
      Article

      Data from the ENVISION and ATLAS trials demonstrated clinically meaningful responses with UGN-102 in the treatment of low-grade, intermediate-risk NMIBC.